Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to the leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs, and sores or wounds on the lower limb that heal slowly, and poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age, and family history.

The intermittent claudication – drugs in development report provides an overview of the intermittent claudication pipeline landscape. It provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

What are the key targets in the intermittent claudication pipeline products market?

The key targets in the intermittent claudication pipeline products market are Fibroblast Growth Factor 2, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase, and Hepatocyte Growth Factor.

Intermittent Claudication Pipeline Products by Targets

Intermittent Claudication Pipeline Products by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the intermittent claudication pipeline products market?

The key mechanisms of action in the intermittent claudication pipeline products market are Fibroblast Growth Factor 2 Activator, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase Activator, and Hepatocyte Growth Factor Activator.

Intermittent Claudication Pipeline Products by Mechanism of Action

Intermittent Claudication Pipeline Products by Mechanism of Action

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the intermittent claudication pipeline products market?

The key routes of administration in the intermittent claudication pipeline products market are intramuscular and sublingual.

Intermittent Claudication Pipeline Products by Routes of Administration

Intermittent Claudication Pipeline Products by Routes of Administration

For more routes of administration insights, download a free report sample

What are the different molecule types in the intermittent claudication pipeline products market?

The different molecule types in the intermittent claudication pipeline products market are gene therapy, cell therapy, and small molecule.

Intermittent Claudication Pipeline Products by Molecule Type

Intermittent Claudication Pipeline Products by Molecule Type

To know more about molecule types, download a free report sample

Which are the major companies in the intermittent claudication pipeline products market?

The major companies in the intermittent claudication pipeline products market are G. Pohl-Boskamp GmbH & Co KG, Helixmith Co Ltd, ID Pharma Co Ltd, and Pluristem Therapeutics Inc.

Intermittent Claudication Pipeline Products by Companies

Intermittent Claudication Pipeline Products by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key targets Fibroblast Growth Factor 2, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase, and Hepatocyte Growth Factor
Key mechanism of action Fibroblast Growth Factor 2 Activator, Guanylate Cyclase (Guanylyl Cyclase or GTP Diphosphate-Lyase Activator, and Hepatocyte Growth Factor Activator
Key routes of administration Intramuscular and Sublingual
Molecule type Gene Therapy, Cell Therapy, and Small Molecule
Major companies G. Pohl-Boskamp GmbH & Co KG, Helixmith Co Ltd, ID Pharma Co Ltd, and Pluristem Therapeutics Inc.

Scope

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in intermittent claudication (cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates intermittent claudication (cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for intermittent claudication (cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

G. Pohl-Boskamp GmbH & Co KG
Helixmith Co Ltd
ID Pharma Co Ltd
Pluristem Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Intermittent Claudication – Overview

Intermittent Claudication – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Intermittent Claudication – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Intermittent Claudication – Companies Involved in Therapeutics Development

G. Pohl-Boskamp GmbH & Co KG

Helixmith Co Ltd

ID Pharma Co Ltd

Pluristem Therapeutics Inc

Intermittent Claudication – Drug Profiles

donaperminogene seltoplasmid – Drug Profile

Product Description

Mechanism Of Action

History of Events

DVC-10101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

emiplacel – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy for Cardiovascular, Dermatology and Neurology – Drug Profile

Product Description

Mechanism Of Action

nitroglycerin – Drug Profile

Product Description

Mechanism Of Action

Intermittent Claudication – Dormant Projects

Intermittent Claudication – Discontinued Products

Intermittent Claudication – Product Development Milestones

Featured News & Press Releases

Nov 12, 2018: New findings from Pluristem’s phase II IC study: PLX-PAD cells significantly improves blood glucose control (HbA1c) and reduce chronic inflammation

Jun 12, 2018: Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study

Jun 04, 2018: Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018

Nov 29, 2017: Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in Ischemic Tissue

May 11, 2017: CHA Biotech Announces Completion of Koreas Phase II Trial in Intermittent Claudication (IC)

Jan 12, 2017: Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication

May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial

Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications

Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea

Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel

Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem’s Phase II Intermittent Claudication Study

Jul 08, 2013: Pluristem’s South Korean Partner Files IND With Korean FDA for PLX Cells

Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study

Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany

Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Intermittent Claudication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Intermittent Claudication – Pipeline by G. Pohl-Boskamp GmbH & Co KG, 2022

Intermittent Claudication – Pipeline by Helixmith Co Ltd, 2022

Intermittent Claudication – Pipeline by ID Pharma Co Ltd, 2022

Intermittent Claudication – Pipeline by Pluristem Therapeutics Inc, 2022

Intermittent Claudication – Dormant Projects, 2022

Intermittent Claudication – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Intermittent Claudication, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.